1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. UK Travel Vaccine Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. UK Travel Vaccine Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. UK Travel Vaccine Market Regional Analysis
6.2 UK Travel Vaccine Market Revenue 2019-2028 (US$ Million)
6.3 UK Travel Vaccine Market Forecast Analysis
7. UK Travel Vaccine Market Analysis – by Product
7.1 Hepatitis A
- 7.1.1 Overview
- 7.1.2 Hepatitis A: UK Travel Vaccine Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Hepatitis B
- 7.2.1 Overview
- 7.2.2 Hepatitis B: UK Travel Vaccine Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Meningococcal Vaccines
- 7.3.1 Overview
- 7.3.2 Meningococcal Vaccines: UK Travel Vaccine Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. UK Travel Vaccine Market Analysis – by Application
8.1 Domestic Travel
- 8.1.1 Overview
- 8.1.2 Domestic Travel: UK Travel Vaccine Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 Outbound Travel
- 8.2.1 Overview
- 8.2.2 Outbound Travel : UK Travel Vaccine Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. UK Travel Vaccine Market – UK Analysis
9.1 Overview
9.2 UK
- 9.2.1 UK Travel Vaccine Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 9.2.1.1 UK Travel Vaccine Market – Revenue and
Forecast Analysis – by Country
- 9.2.1.1 UK:
UK Travel Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
- 9.2.1.1.1 UK: UK Travel Vaccine Market Breakdown, by Product
- 9.2.1.1.2 UK: UK Travel Vaccine Market Breakdown, by Application
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.3 Partnerships and Collaborations
11.4 Other Developments
12. Company Profiles
12.1 GlaxoSmithKline plc.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Merck & Co., Inc.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Sanofi
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Novartis AG
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Pfizer Inc.
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Dynavax Technologies
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Emergent BioSolutions Inc.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Abbott
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Valneva SE
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 SEQIRUS
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
13.1 About Business Market Insights
13.2 List of Abbreviations